SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-018436
Filing Date
2024-02-22
Accepted
2024-02-22 07:45:54
Documents
14
Period of Report
2024-02-22
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ntla-20240222.htm   iXBRL 8-K 41568
2 EX-99.1 ntla-ex99_1.htm EX-99.1 157114
3 GRAPHIC img149557450_0.jpg GRAPHIC 12257
  Complete submission text file 0000950170-24-018436.txt   343659

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ntla-20240222.xsd EX-101.SCH 25022
15 EXTRACTED XBRL INSTANCE DOCUMENT ntla-20240222_htm.xml XML 4763
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 24662340
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)